Great Lakes Retirement Inc. Purchases 179 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Great Lakes Retirement Inc. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,055 shares of the medical research company’s stock after buying an additional 179 shares during the period. Great Lakes Retirement Inc.’s holdings in IQVIA were worth $600,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Compound Global Advisors LLC bought a new stake in shares of IQVIA during the 4th quarter worth $334,000. Peterson Wealth Services boosted its holdings in IQVIA by 19.6% in the 4th quarter. Peterson Wealth Services now owns 1,860 shares of the medical research company’s stock valued at $366,000 after purchasing an additional 305 shares during the period. Summit Trail Advisors LLC boosted its holdings in IQVIA by 46.3% in the 4th quarter. Summit Trail Advisors LLC now owns 1,855 shares of the medical research company’s stock valued at $365,000 after purchasing an additional 587 shares during the period. Savant Capital LLC bought a new stake in IQVIA in the 4th quarter valued at $210,000. Finally, Entropy Technologies LP bought a new stake in IQVIA in the 4th quarter valued at $3,624,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 1.6 %

Shares of IQVIA stock opened at $197.64 on Thursday. The stock has a market capitalization of $35.87 billion, a P/E ratio of 26.35, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day simple moving average of $200.77 and a 200 day simple moving average of $218.81. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on IQV shares. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. Finally, UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.